Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
- New Drug Application for CONTEPO™ submitted to FDA in October 2018 - - Company preparing for potential commercialization of two, first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - DUBLIN, Ireland, Nov. 06, …